Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.

Simon, Renée; Latreille, Jean; Matte, C; Desjardins, Pierre; Boudreault, Katherine; Bergeron, Elizabeth R.

doi:10.1200/jco.2010.28.15_suppl.e11039

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using standardized methods for evaluation of study quality [24,25,27], the research team judged 18 of 51 (35.3%) of the studies pertaining to rates and correlates of adherence to oral antineoplastic therapy to be high risk of bias, as noted in Tables 1 and 3.The most common factors that contributed to high risk of bias ratings included poor specification of target population and convenience sampling methods [16,39,43,[55][56][57][58][59][60][61][62][63], small sample sizes [39, 58-61, 64, 65], lack of clear description of outcomes and/or inadequate measurement of adherence [16,31,39,56,66,67], and low response rate and/or lack of information on nonresponders [30,31,39,43,55,[57][58][59][60][61][62][63][65][66][67], among other factors (supplemental online Appendix 2 provides full criteria and ratings). As shown in Table 2, the research team rated the majority of the intervention studies (58.3% [n 5 7 of 12]) to have high riskof bias, primarily because of use of single-group and nonrandomized study designs [42,46,…”

Section: Evaluation Of Study Quality and Risk Of Biasmentioning

confidence: 99%

A Systematic Review of Adherence to Oral Antineoplastic Therapies

et al. 2016

View full text Add to dashboard Cite

Background. Oral antineoplastic therapies not only improve survival but also reduce the burden of care for patients. Yet patients and clinicians face new challenges in managing adherence to these oral therapies. We conducted a systematic literature review to assess rates and correlates of adherence to oral antineoplastic therapies and interventions aimed at improving adherence. Methods. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a comprehensive literature search of the Ovid MEDLINE database from January 1, 2003 to June 30, 2015, using relevant terminology for oral antineoplastic agents. We included observational, database, and intervention studies. At least two researchers evaluated each paper to ensure accuracy of results and determine risk of bias. Results. We identified 927 records from the search and screened 214 abstracts. After conducting a full-text review of 167

show abstract

Section: Evaluation Of Study Quality and Risk Of Biasmentioning

confidence: 99%

A Systematic Review of Adherence to Oral Antineoplastic Therapies

et al. 2016

View full text Add to dashboard Cite

show abstract

“…80%), and those who reported missing $ 3 days in the last 2 weeks were considered nonadherent (, 80%). 7 Women who were nonadherent or who discontinued treatment were grouped as nonadherent for analyses.…”

Section: Participantsmentioning

confidence: 99%

“…[4][5][6] ET is a highly effective adjuvant treatment associated with a 40% reduction in BC recurrence and 30% reduction in BCrelated mortality. [7][8][9][10][11][12] Despite its clinical benefits, 10% to 30%…”

Section: Introductionmentioning

confidence: 99%

“…[8][9][10][11][12] Underuse is concerning, because women who are inconsistent in medication use or discontinue ET before 5 years do not realize full benefits. 7,12,13 Specifically, women who underuse ET have worse BC outcomes (ie, BC recurrence and survival) compared with women who adhere to ET for 5 years. 5,13 ET is associated with adverse effects and poor healthrelated quality of life (HRQOL).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer

Pinheiro

Wheeler

Reeder‐Hayes

et al. 2017

JOP

View full text Add to dashboard Cite

Purpose: Endocrine therapy (ET) underuse puts women at increased risk for breast cancer (BC) recurrence. Our objective was to determine if health-related quality of life (HRQOL) subgroups were associated with underuse. Methods: Data came from the third phase of the Carolina Breast Cancer Study. We included 1,599 women with hormone receptor–positive BC age 20 to 74 years. HRQOL was measured, on average, 5 months postdiagnosis. Subgroups were derived using latent profile (LP) analysis. Underuse was defined as not initiating or adhering to ET by 36 months postdiagnosis. Multivariable logistic regression models estimated adjusted odds ratios (ORs) between HRQOL LPs and underuse. The best HRQOL LP was the reference. Chemotherapy- and race-stratified models were estimated, separately. Results: Initiation analyses included 953 women who had not begun ET by their 5-month survey. Of these, 154 never initiated ET. Adherence analyses included 1,114 ET initiators, of whom 211 were nonadherent. HRQOL was not significantly associated with noninitiation, except among nonchemotherapy users, with membership in the poorest LP associated with increased odds of noninitiation (adjusted OR, 5.5; 95% CI, 1.7 to 17.4). Membership in the poorest LPs was associated with nonadherence (LP1: adjusted OR, 2.2; 95% CI, 1.2 to 4.0 and LP2: adjusted OR,1.9; 95% CI, 1.1 to 3.6). Membership in the poorest LP was associated with nonadherence among nonchemotherapy users (adjusted OR, 2.1; 95% CI, 1.2 to 5.1). Conclusion: Our results suggest women with poor HRQOL during active treatment may be at increased risk for ET underuse. Focusing on HRQOL, a modifiable factor, may improve targeting of future interventions early in the BC continuum to improve ET initiation and adherence and prevent BC recurrence.

show abstract

“…sociodemographic characteristics -age at diagnosis (until 40 years old; 50-69 years old; 70 years old or older) 18 ; educational level in years of complete studies (low, ; comorbidities described in medical record (yes or no); family history of cancer; Charlson comorbidity index (CCI) 21 (attributing two points in the report of only one neoplasm, and three points, four or more according to the quantity of self-reported comorbidities); 3. support characteristics -kind of hormonal therapy (TMX or anastrozole); performance of chemotherapy, radiotherapy and surgery; number of appointments in clinical oncology (up to 13 appointments and 14 or more) 6 ; number of hospitalizations during the observation period (none; up to 2; 3 or more) 19 .…”

Section: Methodsmentioning

confidence: 99%

Fatores associados à adesão e à persistência na hormonioterapia em mulheres com câncer de mama

Guedes¹,

Guerra

Alvim

et al. 2017

Rev. bras. epidemiol.

View full text Add to dashboard Cite

Introduction: Hormonal therapy in breast cancer is essential to the transition from active treatment to care survival, because it improves long-term survival and provides a better quality of life. reducing hospital costs as well. However, adherence and persistence in the recommended treatment are important to achieve the desirable results. Methodology: This is a cohort retrospective study of 182 women on hormonal treatment identified at a high complexity oncology unit, in the southeastern region of Brazil, and followed-up until 2014. We performed a bivariate analysis to analyze the factors associated with adherence and we conducted the multivariate Cox regression to identify variables associated with discontinuity of treatment over time. Results: Overall adherence was 85.2% and persistence was 45.4% at the end of 5 years. No association was found between the studied independent variables and adherence. Women with advanced stage (HR = 2.24; 95% confidence interval 1.45 -3.45), who did not undergo surgery (HR = 3.46; 95%CI 2.00 -5.97), and with three or more hospitalizations (HR = 6.06; 95%CI 2.53 -14.54) exhibited increased risk of discontinuity. Discussion: The variables associated with persistence reflect the relation between the highest disease severity and the discontinuity of adjuvant hormonal treatment. Conclusion: Despite the high adherence level, there is a progressive increase in non-persistence among women on hormonal therapy, influenced by characteristics related to disease severity, which contributes to an inadequate therapeutic response.

show abstract

Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.

Cited by 4 publications

References 0 publications

A Systematic Review of Adherence to Oral Antineoplastic Therapies

A Systematic Review of Adherence to Oral Antineoplastic Therapies

Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer

Fatores associados à adesão e à persistência na hormonioterapia em mulheres com câncer de mama

Contact Info

Product

Resources

About